Evidence map›Paper›PMID 38026290›Full record

ArticleFrontiers in public health2023

Public perceptions of the FDA's marketing authorization of Vuse on Twitter/X.

Sarah Lee, Zidian Xie, Emily Xu, Yihan Shao, Deborah J Ossip, Dongmei Li

Abstract read
In one paragraph

Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sarah LeeGoergen Institute for Data Science, University of Rochester, Rochester, NY, United States.
Zidian XieDepartment of Clinical & Translational Research, University of Rochester Medical Center, Rochester, NY, United States.
Emily XuGoergen Institute for Data Science, University of Rochester, Rochester, NY, United States.
Yihan ShaoGoergen Institute for Data Science, University of Rochester, Rochester, NY, United States.
Deborah J OssipDepartment of Public Health Sciences, University of Rochester Medical Center, Rochester, NY, United States.
Dongmei LiDepartment of Clinical & Translational Research, University of Rochester Medical Center, Rochester, NY, United States.

Funding

WNY Center for Research on Flavored Tobacco Products (CRoFT)U54CA228110 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI OSSIP, DEBORAH J · 2018 to 2022
$19.8M
NCI NIH HHS U54 CA228110
6 · The paper itself

Abstract

Introduction: On October 12, 2021, the FDA issued its first marketing granted orders for Vuse, the e-cigarette product by R.J. Reynolds Vapor Company. The public perceptions and reactions to the FDA's Vuse authorization are prevalent on social media platforms such as Twitter/X. We aim to understand public perceptions of the FDA's Vuse authorization in the US using Twitter/X data. Methods: Through the Twitter/X streaming API (Application Programming Interface), 3,852 tweets between October 12, 2021, and October 23, 2021, were downloaded using the keyword of Vuse. With the elimination of retweets, irrelevant tweets, and tweets from other countries, the final dataset consisted of 523 relevant tweets from the US. Based on their attitudes toward the FDA authorization on Vuse, these tweets were coded into three major categories: positive, negative, and neutral. These tweets were further manually classified into different categories based on their contents. Results: There was a large peak on Twitter/X mentioning FDA's Vuse authorization on October 13, 2021, just after the authorization was announced. Of the 523 US tweets related to FDA's Vuse authorization, 6.12% ( Discussion: Public perceptions and discussions on Twitter/X regarding the FDA's Vuse authorization in the US showed that Twitter/X users were more likely to show a negative than a positive attitude with a major concern about health risks.

Indexed as

Electronic Nicotine Delivery SystemsSocial MediaHumansMarketingPublic Opinionauthorizatione-cigarettesFDATwitter/XVuse

Identifiers

PMID38026290
PMCPMC10654997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.